AZR MEXC RealStocks
Own real AZR shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 13:50:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Azora Therapeutics, Inc. (AZR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.68, with a market capitalization of $9.87M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.02 to $4.97. This page covers its latest market performance, valuation, price trends and company information.
$9.87M | |
$3.68 | |
$3.68 | |
$3.68 | |
$3.51 | |
2.00 | |
62.28K | |
-- | |
$4.97 | |
$3.02 | |
-- | |
-- |
Azora Therapeutics, Inc. (AZR) is trading at $3.68 in pre-market trading as of 2026-11-12 11:26:00, up 4.84% ($0.17) from the previous close of $3.51
Pre-market trading shows how investors are pricing AZR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Azora Therapeutics, Inc. (AZR) moved from $4.15 to $3.68, representing a decline of 11.33% ($0.47).
The stock traded between $3.35 and $4.39 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 37.60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 33.8%
AZR is currently trading at $3.68, placing it 33.8% of the way from its 52-week low of $3.02 to its 52-week high of $4.97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Azora Therapeutics, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Azora Therapeutics, Inc. (AZR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AZR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AZR shares and USD.
AZR Shares to USD
1.00 AZR shares = 3.68 USD
Calculations are estimates based on the latest available price and are for reference only.